A biosimilar of rituximab versus innovator rituximab in patients with diffuse large B-cell lymphoma

Trial Profile

A biosimilar of rituximab versus innovator rituximab in patients with diffuse large B-cell lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2012

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Jul 2012 New trial record
    • 17 Jun 2012 Interim results presented at the 17th Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top